Study Evaluating Sirolimus in Kidney Transplant Recipients. - Full Text View - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Study Evaluating Sirolimus in Kidney Transplant Recipients.

This study has been completed.

First Received on September 9, 2005. Last Updated on March 13, 2008 History of Changes

Sponsor:	Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:	Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:	NCT00167947

Purpose

Renal function at 12 months assessed by calculated creatinine clearance.

Condition	Intervention	Phase
Kidney Failure Graft vs Host Disease	Drug: Cyclosporine Drug: Steroids Drug: Rapamune (Sirolimus)	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Randomized, Open Label Study to Evaluate the Effects of a Regimen With Sirolimus,Low Doses Cyclosporine and Steroids vs a Regimen With Sirolimus and Steroids, After an Induction Period With Basiliximab, Sirolimus,Cyclosporine and Steroids in de Novo Renal Transplant Patients.

Resource links provided by NLM:

MedlinePlus related topics: Kidney Transplantation

Drug Information available for: Sirolimus Cyclosporine Cyclosporin Everolimus CCI 779

U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:

To evaluate the safety and efficacy of an immunosuppressive regimen using synergic action of SRL and CsA, but which will limit (ab initio), the nephrotic effect of such combination. To compare Rapamune/low dose Cyclosporine vs. Rapamune/Steroids. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	150
Study Start Date:	January 2005
Study Completion Date:	July 2007
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Assigned Interventions

Active Comparator: A

Drug: Cyclosporine

Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

Drug: Steroids

Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

Drug: Rapamune (Sirolimus)

Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

Experimental: B

Drug: Cyclosporine

Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

Drug: Steroids

Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

Drug: Rapamune (Sirolimus)

Arm 1= Rapamune+ low dose Cyclosporine+steroids "Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age is older than 18 years.
End-stage renal disease, with subjects scheduled for kidney transplant.
Women of childbearing potential must not be pregnant and agree to medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of assigned treatment.

Other inclusion applies.

Exclusion Criteria:

Evidence of active systemic or localized major infection.
Use of any investigational drug or treatment up to 4 weeks prior to study entry.
Known hypersensitivity to SRL or its derivatives, macrolide antibiotics, corticosteroids, basiliximab.
Multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant).
Immunosuppression therapies other than those allowed in the protocol.
Treatment with voriconazole, terfenadine, cisapride, astemizole, pimozide, or ketoconazole (all known to interact with SRL) that is not discontinued prior to study entry.

Other exclusion applies.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167947

Locations

Italy

Roma, Lazio, Italy, 00168

Roma, Lazio, Italy, 00144

Palermo, Sicily, Italy, 90127

Bari, Italy, 70100

Bologna, Italy, 40138

Cagliari, Italy, 09125

Firenze, Italy, 50139

L'Aquila, Italy, 67100

Milano, Italy, 20162

Pisa, Italy, 56100

Sassari, Italy, 07100

Siena, Italy, 53100

Udine, Italy, 37100

Varese, Italy, 21100

Sponsors and Collaborators

Wyeth is now a wholly owned subsidiary of Pfizer

Investigators

Study Director:	Medical Monitor	Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator:	Trial Manager	For Italy, decresg@wyeth.com

More Information

No publications provided

Responsible Party:	Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier:	NCT00167947 History of Changes
Other Study ID Numbers:	0468E-101629
Study First Received:	September 9, 2005
Last Updated:	March 13, 2008
Health Authority:	Italy: Ministry of Health

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Kidney
Transplant

Additional relevant MeSH terms:

Graft vs Host Disease
Renal Insufficiency
Immune System Diseases
Kidney Diseases
Urologic Diseases
Cyclosporins
Cyclosporine
Sirolimus
Everolimus
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Dermatologic Agents
Antirheumatic Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on February 09, 2012

Back to top of Main Content